Breaking Finance News

Zacks Investment Research downgraded Varex Imaging Corp (NASDAQ:VREX) to Hold in a statement released earlier today.

Having a price of $33.61, Varex Imaging Corp (NASDAQ:VREX) traded 1.53% higher on the day. The last closing price is up -10.51% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. The company has recorded a 50-day moving average of $31.81 and a 200-day moving average of $32.53. 296,093 shares of the stock were exchanged, down from an average trading volume of 390,217

Zacks Investment Research has downgraded Varex Imaging Corp (NASDAQ:VREX) to Hold in a report released on 07/07/2017.

On 6/22/2017, Zacks Investment Research released a statement for Varex Imaging Corp (NASDAQ:VREX) bumped up the target price from $0.00 to $39.00 that suggested an upside of 0.14%.

See Chart Below

Varex Imaging Corp (NASDAQ:VREX)

Varex Imaging Corp has 52 week low of $25.00 and a 52 week high of $36.58 with a PE ratio of 18.62 and has a market capitalization of $0.

Brief Synopsis On Varex Imaging Corp (NASDAQ:VREX)

Varex Imaging Corporation is a supplier of medical X-ray tubes and image processing solutions. The Company's segments include Medical and Industrial. The X-ray imaging system manufacturers use the Company's components for medical imaging, cargo screening and border security, to detect, diagnose and protect. The Medical business segment designs, manufactures, sells and services X-ray imaging components for use in a range of applications, including radiographic or fluoroscopic imaging, mammography, special procedures, computed tomography, radiation therapy and computer-aided detection. The Industrial business segment designs, manufactures, sells and services products for use in security and industrial inspection applications, such as cargo screening at ports and borders and non-destructive examination in a range of applications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *